Webinar Presentation

Date: June 11th, 2013

Novartis Thalassemia App Challenge

On today’s call:

JL Neptune Senior Vice President

Health 2.0

Aya Yamaura-Timms Product Director,

EXJADE Global Brand Team

Novartis Oncology

Graeme Ossey Challenge Manager

Health 2.0

Laszlo Danko Senior Director

EXJADE Global Brand Team

Novartis Oncology

Agenda for Today’s Meeting

Novartis Oncology Overview

Thalassemia Background

Challenge & Goals

About the Phases

Evaluation Criteria

Timeline

Q & A

Novartis Oncology Overview

Novartis Oncology has become a global leader in oncology and hematology through targeted research and open partnership in the pursuit of new therapies capable of transforming outcomes for people with cancer and other hematological diseases.

We offer a wide range of innovative therapies to help physicians meet patient needs, with one of the broadest and most comprehensive oncology pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy, focusing on unmet medical needs and disease pathways.

For more information about how we are transforming the treatment of cancer and other diseases, visit www.novartisoncology.com.

Thalassemia Background

Diverse family of genetic disorders affecting red blood cell production, causing anemia and significant complications.1

Thalassemia can range from milder types to severe cases starting in infancy and require regular blood transfusions for patient survival.2

Clinical complications can vary by type, and patients suffer from iron overload in their bodies as a consequence of the disease or because of extra iron absorbed from transfusions.3

Most patients with thalassemia are of South and Southeast Asian, Mediterranean or Middle East origin, with immigration broadening the global prevelance.4

1. Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Reviews. 2012:26S:S3-S6

2. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates

across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115:1886-1892.

3. Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Reviews. 2012;26S:S16-19.

4. Thalassaemia International Federation. The Thalassaemia International Federation’s (TIF) New Focus: Addressing the Management of Non-Transfusion-Dependent

Thalassaemias (NTDT). Position Paper 5.2. March 20, 2012. Accessed at: http://www.thalassaemia.org.cy/pdf/NTDT_Position_Paper_Final.pdf.

The Challenge

Novartis challenges the teams to develop an innovative smartphone/iPad application that increases Thalassemia patients’ (as well as the caretakers’) ability to manage the disease effectively and

help patients live active lives despite their condition, in ways including:

Monitoring/tracking of key parameters

Treatment/medication adherence

Recording of daily personal facts

Thalassemia Disease Management App

7

Patient (THAL App is on smart

phone )

HCP

Patient (THAL App is on smart

phone )

Key metrics

Motivational factors

Gamification/Edutainment

Geo-targeting

•Help Thalassemia patients communicate better with their doctors and manage the disease better •Improved monitoring and compliance leading to better outcome

App Challenge Goals

Teams should be BOLD and INNOVATIVE in developing solutions that:

• Motivate, inspire and reinforce positive behaviors related to adherence

• Enable patients to set and track goals, motivated by gaming features, “awards”/incentives, daily inspiration, etc.

• Provide users ability to share information and collaborate with others

(most importantly with their doctors)

• Educate, entertain and keep patient up-to-date on disease and lifestyle topics

The Challenge

Phase I – Ideation

• Submission requirements: concept mock-up and documentation

• Awards: 5 finalists awarded $5,000 each and continue to Phase II

Phase II – Development

• Eligibility: Phase I finalist

• Submission requirements: demo video, slide deck, and live demo plus submission of app for testing

• Awards: First Place $100,000

Second Place $20,000

Third Place $5,000

Evaluation Criteria

Phase I

• Creativity, innovation and unique qualities of application

- (i.e. Game and/or gamification design characteristics that clearly drive engagement and experience)

• Design, usability and intuitiveness of application

• User appeal (simple and attractive interface) and potential for widespread adoption (global audience)

• Capability for the app to be connected (via opt-in-feature) to the tools (smartphones, tablets, PCs) used by HCPs for sharing of data

• Potential of partnership and future work with Novartis

Evaluation Criteria

Phase II

• All phase I criteria

• Degree of development of application

- (prototype vs. polished product)

Timeline

Phase I submission deadline: June 30, 2013

• Evaluation Period: July 1 – 12, 2013

• Notification to Finalists: Week of July 15, 2013

Phase II submission deadline: Sept. 8, 2013

• Live, Virtual Judging: Sept. 10, 2013

Winner announced:

October 1, 2013

Health 2.0 Fall 2013 Conference

Santa Clara, CA

Resources

Thalassemia International Federation - http://www.thalassaemia.org.cy/

Cooley’s Anemia Foundation - http://www.thalassemia.org/

Novartis Iron Health Alliance - http://www.ironhealthalliance.com/index.jsp

United Kingdom Thalassaemia Society, or UKTS - http://www.ukts.org/

Thalassemia Foundation of Thailand - http://www.thalassemia.or.th/index.html

Thalassemia Patients and Friends (ThalPal - USA) -http://www.thalassemiapatientsandfriends.com/

Thalassemics India - http://www.thalassemicsindia.org/

National Thalassemia Welfare Society (India) - http://thalassemiaindia.org/index.php

Questions?

www.health2challenge.com

Contact Graeme Ossey at:

Graeme@health2con.com